Transarterial Radioembolization for Management of Hepatocellular Carcinoma

Oncologist. 2023 Dec 21:oyad327. doi: 10.1093/oncolo/oyad327. Online ahead of print.ABSTRACTTransarterial radioembolization (TARE) with Yttrium-90 (Y90) is a growing area of study due to its benefits in early-, intermediate-, and late-stage hepatocellular carcinoma. Treatment intent, including curative therapy, bridging to transplant, and downstaging disease, informs treatment approach and dosimetry goals. Radiation lobectomy (RL) and radiation segmentectomy (RS) are the 2 main forms of Y90 administration which have shown improved survival outcomes with the development of personalized dosimetry. RS aims to achieve complete pathological necrosis with dose escalation and RL aims for local disease control as well as induction of contralateral lobe hypertrophy to improve hepatic reserve. Furthermore, TARE has been validated in head-to-head comparison to other locoregional and systemic therapies. Lastly, early potential exists for combination therapy between TARE and immune checkpoint inhibitors for advanced stage disease.PMID:38128565 | DOI:10.1093/oncolo/oyad327
Source: The Oncologist - Category: Cancer & Oncology Authors: Source Type: research